Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 7/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR3A | P46098 | 4/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.40 |
| ▸ | HTR3B | O95264 | 2/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7923474 | 0.98 | ADRB1 (0.46) | ADRB1HTR7HTR2CHTR3AHTR3E | |
| SCHEMBL9024972 | 0.82 | L3MBTL1 (0.42) | — | |
| Bromide SCHEMBL7296632 | 0.80 | L3MBTL1 (0.41) | — | |
| SCHEMBL13322698 | 0.78 | POLB (0.42) | ADRB1HTR7HTR2CHTR3AHTR3E | |
| SCHEMBL13354917 | 0.77 | HTR2C (0.41) | ADRB1HTR2CHTR3AHTR3EHTR3B | |
| SCHEMBL336258 | 0.73 | ADRB1 (0.52) | ADRB1HTR7HTR2CHTR3AHTR3E | |
| SCHEMBL11377242 | 0.70 | HRH1 (0.48) | — | |
| SCHEMBL21775839 | 0.69 | ADRB1 (0.47) | ADRB1HTR7HTR2CHTR3AHTR3E | |
| SCHEMBL7827205 | 0.68 | TAAR1 (0.49) | ADRB1HTR2CHTR3AHTR3EHTR3B | |
| SCHEMBL15219304 | 0.68 | ADRB1 (0.42) | ADRB1HTR7HTR3AHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074873-A | 7- (morpholinyl) -2- (N-piperazinyl) methylthioeno [2, 3-c ] pyridine derivatives as anticancer agents | 纳科法尔马有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1531822-B1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7449576-B1 | potent antagonists of the CCR1 receptor; inflammation; (5-Chloro-2-piperazin-1-yl-phenyl)-phenyl-methanone | CHEMOCENTRYX, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| EP-1531822-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | Chemocentryx, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003105853-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-6221868-B1 | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0995741-A1 | REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-26 | — | — | EP | disclosed |
| EP-0333137-A1 | Arylpiperazinylalkoxy derivatives of cyclic imides, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-09-20 | — | — | EP | disclosed |
| US-4826846-A | ANALGESIC, ANTIPSYCHOTIC | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-05-02 | — | — | US | disclosed |
| US-4780466-A | ANALGESICS, ANTIPSYCHOTIC AGENTS, ANXIOLYTIC AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-10-25 | — | — | US | disclosed |
| US-4267328-A | USEFUL AS ANALGESICS OR PSYCHOTROPIC AGENTS | SYNTHELABO (FR) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | ADRB1 294/4885HTR7 559/4885HTR2C 547/4885 |
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | ADRB1 294/4885HTR7 559/4885HTR2C 547/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | ADRB1 230/4885HTR7 461/4885HTR2C 547/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | ADRB1 294/4885HTR7 559/4885HTR2C 547/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | ADRB1 230/4885HTR7 461/4885HTR2C 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.